GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.
Financial Results:
Glaxosmithkline Pharmaceuticals Ltd reported Revenues for Q2FY24 of ₹957.00 Crores up from ₹917.00 Crore year on year, a rise of 4.36%.
Total Expenses for Q2FY24 of ₹686.00 Crores up from ₹676.00 Crores year on year, a rise of 1.48%.
Consolidated Net Profit of ₹218.00 Crores up 12.95% from ₹193.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹12.84, up 12.43% from ₹11.42 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.